IBJNews

Lilly reacquires migraine medicine after encouraging results

Back to TopCommentsE-mailPrintBookmark and Share

More than two years after selling rights to an experimental migraine treatment to an outside firm, Eli Lilly and Co. announced Monday it is buying the drug back.

Positive results from a Phase 2 trial in patients convinced the Indianapolis-based drugmaker to reacquire the medicine, which goes by the name LY2951742. Lilly will likely conduct a Phase 3 trial, the last stage of testing before it can submit the drug for market approval.

The drug was licensed from Lilly in 2011 by Massachusetts-based Arteaus Therapeutics, a company formed at the same time by two venture capital firms, OrbiMed and Atlas Venture.

Lilly did not disclose the financial terms of its deal with Arteaus. However, Lilly will record a fourth-quarter charge of $57.1 million to reflect the reacquisition costs and Lilly’s assumption of ongoing development expenses of the drug.

The drug, which is known as a calcitonin gene-related peptide, or CGRP, antibody, was discovered by Lilly scientists. It is one of nine experimental drugs Lilly has licensed to outside firms as a way to share the risk of research and development costs. Lilly calls this risk-sharing arrangement with venture capital firms its Capital Funds Portfolio.

The migraine medicine is the first one Lilly has reacquired from a participating venture-backed drug company.

“Through this strategy, independent investment firms and portfolio companies provide a unique way to access, share risks, and expand funding to develop molecules, such as the CGRP antibody, to help speed the delivery of timely valued medicines to patients who are waiting,” said Jan M. Lundberg, president of Lilly Research Laboratories, the R&D arm of Lilly.

Lundberg helped discover the characteristics of CGRP 30 years ago as a researcher in Sweden, according to Reuters.

Lilly--along with New Jersey-based Merck & Co. Inc., Germany-based Beohringer Ingelheim GmbH and other drugmakers--has been trying to develop CGRP-antibodies because no other drugs are effective over the long term at alleviating migraine headaches.

The number of Americans that suffer from migraines each year is estimated to be at least 9 million and as high as 30 million. Without an effective drug, patients seek relief from a bevy of other treatments, including acupuncture, chiropractic therapy and even Botox.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. With Pence running the ship good luck with a new government building on the site. He does everything on the cheap except unnecessary roads line a new beltway( like we need that). Things like state of the art office buildings and light rail will never be seen as an asset to these types. They don't get that these are the things that help a city prosper.

  2. Does the $100,000,000,000 include salaries for members of Congress?

  3. "But that doesn't change how the piece plays to most of the people who will see it." If it stands out so little during the day as you seem to suggest maybe most of the people who actually see it will be those present when it is dark enough to experience its full effects.

  4. That's the mentality of most retail marketers. In this case Leo was asked to build the brand. HHG then had a bad sales quarter and rather than stay the course, now want to go back to the schlock that Zimmerman provides (at a considerable cut in price.) And while HHG salesmen are, by far, the pushiest salesmen I have ever experienced, I believe they are NOT paid on commission. But that doesn't mean they aren't trained to be aggressive.

  5. The reason HHG's sales team hits you from the moment you walk through the door is the same reason car salesmen do the same thing: Commission. HHG's folks are paid by commission they and need to hit sales targets or get cut, while BB does not. The sales figures are aggressive, so turnover rate is high. Electronics are the largest commission earners along with non-needed warranties, service plans etc, known in the industry as 'cheese'. The wholesale base price is listed on the cryptic price tag in the string of numbers near the bar code. Know how to decipher it and you get things at cost, with little to no commission to the sales persons. Whether or not this is fair, is more of a moral question than a financial one.

ADVERTISEMENT